Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

First-in-man intravenous implantation of stromal vascular fraction in psoriasis: a case study.

Comella K, Parlo M, Daly R, Dominessy K.

Int Med Case Rep J. 2018 Mar 21;11:59-64. doi: 10.2147/IMCRJ.S163612. eCollection 2018.

2.

Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction.

Comella K, Parlo M, Daly R, Depasquale V, Edgerton E, Mallory P, Schmidt R, Drake WP.

J Clin Med Res. 2017 Nov;9(11):935-942. doi: 10.14740/jocmr3187w. Epub 2017 Oct 2.

3.
4.

Autologous Stromal Vascular Fraction in the Intravenous Treatment of End-Stage Chronic Obstructive Pulmonary Disease: A Phase I Trial of Safety and Tolerability.

Comella K, Blas JAP, Ichim T, Lopez J, Limon J, Moreno RC.

J Clin Med Res. 2017 Aug;9(8):701-708. doi: 10.14740/jocmr3072w. Epub 2017 Jul 1.

5.

Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritis.

Bansal H, Comella K, Leon J, Verma P, Agrawal D, Koka P, Ichim T.

J Transl Med. 2017 Jun 19;15(1):141. doi: 10.1186/s12967-017-1242-4.

6.

Erratum to: Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease.

Comella K, Silbert R, Parlo M.

J Transl Med. 2017 May 22;15(1):108. doi: 10.1186/s12967-017-1217-5. No abstract available.

7.
8.

Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy.

Comella K, Parcero J, Bansal H, Perez J, Lopez J, Agrawal A, Ichim T.

J Transl Med. 2016 Jun 2;14(1):158. doi: 10.1186/s12967-016-0918-5.

9.

Integration of Stem Cell to Chondrocyte-Derived Cartilage Matrix in Healthy and Osteoarthritic States in the Presence of Hydroxyapatite Nanoparticles.

Dua R, Comella K, Butler R, Castellanos G, Brazille B, Claude A, Agarwal A, Liao J, Ramaswamy S.

PLoS One. 2016 Feb 12;11(2):e0149121. doi: 10.1371/journal.pone.0149121. eCollection 2016.

10.

Characterization of antibody binding to three cancer-related antigens using flow cytometry and cell tracking velocimetry.

Chosy EJ, Nakamura M, Melnik K, Comella K, Lasky LC, Zborowski M, Chalmers JJ.

Biotechnol Bioeng. 2003 May 5;82(3):340-51.

PMID:
12599261
11.

Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system.

Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, Caligiuri MA, Chalmers JJ.

Cytometry. 2001 Dec 1;45(4):285-93.

PMID:
11746098
12.

Mobility measurements of immunomagnetically labeled cells allow quantitation of secondary antibody binding amplification.

McCloskey KE, Comella K, Chalmers JJ, Margel S, Zborowski M.

Biotechnol Bioeng. 2001 Dec 20;75(6):642-55.

PMID:
11745142
13.

Separation of a breast cancer cell line from human blood using a quadrupole magnetic flow sorter.

Nakamura M, Decker K, Chosy J, Comella K, Melnik K, Moore L, Lasky LC, Zborowski M, Chalmers JJ.

Biotechnol Prog. 2001 Nov-Dec;17(6):1145-55.

PMID:
11735453
14.

Evaluation of eluents from separations of CD34+ cells from human cord blood using a commercial, immunomagnetic cell separation system.

Melnik K, Nakamura M, Comella K, Lasky LC, Zborowski M, Chalmers JJ.

Biotechnol Prog. 2001 Sep-Oct;17(5):907-16.

PMID:
11587583
15.

Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization.

Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG.

Am Heart J. 2001 Jul;142(1):72-4.

PMID:
11431659

Supplemental Content

Loading ...
Support Center